Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.90
-0.0100-0.34%
Post-market: 2.900.00000.00%19:30 EDT
Volume:217.88K
Turnover:632.00K
Market Cap:100.82M
PE:-9.35
High:2.96
Open:2.93
Low:2.86
Close:2.91
52wk High:5.46
52wk Low:2.32
Shares:34.76M
Float Shares:32.61M
Volume Ratio:0.66
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3100
EPS(LYR):-0.3367
ROE:-73.17%
ROA:-41.93%
PB:6.97
PE(LYR):-8.61

Loading ...

Anixa Biosciences Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Sep 05

Anixa Biosciences CEO Presents at NASDAQ-LD Micro SF Summit

Reuters
·
Sep 03

Anixa Says Phase 1 Breast Cancer Vaccine Trial Meets Endpoints, Phase 2 Preparations Underway

Reuters
·
Aug 24

Anixa Biosciences Presents at Cantor Fitzgerald Global Healthcare Conference on Breast Cancer Vaccine Progress

Reuters
·
Aug 24

Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks

Simply Wall St.
·
Aug 21

Anixa Biosciences to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Aug 18

Top Executive Makes Bold Move With Fresh Anixa Biosciences Stock Buy

TIPRANKS
·
Aug 04

Anixa Biosciences CEO Amit Kumar Acquires 5,000 Common Shares Valued at $17,350

Reuters
·
Aug 03

Anixa Biosciences CEO Quietly Boosts His Stake With Fresh Insider Buys

TIPRANKS
·
Jul 28

Anixa Biosciences CEO Amit Kumar Acquires 3,000 Common Shares Worth $11,190

Reuters
·
Jul 27

Anixa Biosciences CEO Amit Kumar Acquires 5,000 Common Shares for $17,300

Reuters
·
Jul 21

Insider Move: Anixa Biosciences Director Deepens Stake in the Company

TIPRANKS
·
Jul 21

Anixa Biosciences Director Lewis H. Titterton Jr Acquires 12,000 Common Shares Valued at $41,640

Reuters
·
Jul 21

3 Penny Stocks With Market Caps Over $100M To Consider

Simply Wall St.
·
Jul 20

Anixa Biosciences Director Lewis H. Titterton Jr Acquires $9,172 of Common Shares

Reuters
·
Jul 16

Anixa Biosciences Says Australia Accepts Patent for Breast Cancer Vaccine Technology

Reuters
·
Jul 14

Anixa Biosciences CEO Amit Kumar Buys $15,200 Common Shares

Reuters
·
Jul 13

Anixa Advances Ovarian Cancer CAR-T Trial to Highest Dose Cohort in Phase 1 Study

Reuters
·
Jul 06

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - Five Patients Surpass One Year Survival with Durations up to 28 Months

THOMSON REUTERS
·
Jul 06